Walleye Capital LLC grew its position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 17.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 302,642 shares of the company's stock after acquiring an additional 45,225 shares during the quarter. Walleye Capital LLC owned about 0.48% of ABIVAX Société Anonyme worth $2,215,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of ABVX. ADAR1 Capital Management LLC boosted its position in shares of ABIVAX Société Anonyme by 190.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock valued at $11,078,000 after acquiring an additional 991,781 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $5,336,000. Springhill Fund Asset Management HK Co Ltd purchased a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $1,520,000. Franklin Resources Inc. raised its holdings in ABIVAX Société Anonyme by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock valued at $10,732,000 after buying an additional 141,710 shares during the period. Finally, abrdn plc raised its holdings in ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock valued at $3,105,000 after buying an additional 107,750 shares during the period. 47.91% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. JMP Securities restated a "market outperform" rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $38.00.
View Our Latest Stock Analysis on ABVX
ABIVAX Société Anonyme Price Performance
Shares of ABVX traded up $0.45 during mid-day trading on Thursday, hitting $7.22. The company's stock had a trading volume of 40,814 shares, compared to its average volume of 130,725. The company's 50-day moving average is $6.67 and its 200-day moving average is $7.66. ABIVAX Société Anonyme has a 52-week low of $4.77 and a 52-week high of $16.63.
ABIVAX Société Anonyme Profile
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Articles
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
